Global advocacy

The growing burden of non-communicable diseases (NCDs) - including the diabetes pandemic - requires global concerted action. Novo Nordisk works actively to prevent and control diabetes and other major chronic conditions through partnerships and advocacy work at large. The primary objective of this work is to accelerate action towards the achievement of global goals on health and the wider Sustainable Development Goals (SDG) framework.   


In our efforts to address social determinants of health and improve access to diabetes care we are proud to partner with people living with NCDs as well as experts from around the world. At Novo Nordisk, advocacy is anchored in the company’s Triple Bottom Line approach and integrated into how we do business.

 

Our external advocacy partners include:

  • Individual patient representatives and patient associations
  • Government representatives and policymakers
  • Multi- and bilateral agencies and organisations
  • Healthcare authorities and providers including community health workers
  • Civil society organisations, foundations, alliances and professional societies
  • Academic institutions
  • Key opinion leaders 

Examples of global advocacy partners:

 

NCD Alliance (NCDA)

Novo Nordisk has been a corporate supporter of the NCDA for many years and we work closely together on NCD advocacy. We fully support the NCDA vision of ‘a world where everyone has the opportunity for a healthy life, free from preventable suffering, stigma and death caused by NCDs.

Throughout the years, we have worked with NCDA to call attention to keys opportunities and challenges relating to the NCD agenda such as the need to prioritise NCD prevention and control as part of the sustainable development agenda; the lack of financing for NCDs; the need for addressing NDCs in relation to maternal health; and the need to improve access to NCD care in low and middle income countries.

We applaud the NCDA for their efforts to strengthen the voices of people living with and affected by NCDs. The launch of the first-ever Advocacy Agenda of People Living with NCDs was a key milestone. We are proud to have supported the East African NCD Alliance to ensure that voices from across East Africa were also heard in the ‘Our Views, Our Voices’ initiative, which formed the basis of the Advocacy Agenda. 

Ultimately, a strengthened, collective voice of people living with NCDs significantly increases the possibility of gaining political traction and accelerating action at local and global levels.

 

Find out more about the NCD Alliance


International Diabetes Federation (IDF)

Novo Nordisk has a long-standing partnership with IDF. The most successful collaborations include the UN Resolution on Diabetes (2006), the UN High-Level Meeting on NCDs (2011), our DAWN project (2011-2013), NCDs and the 2030 Agenda for Sustainable Development (through NCD Alliance), numerous Diabetes Leadership Forums and World Diabetes Day. In addition, Novo Nordisk also has a significant presence at IDF Congresses. 

Why Novo Nordisk collaborates with IDF

IDF is the strongest leading voice and only global advocate for people with diabetes, their families and healthcare providers. The main purpose of our collaboration is to improve diabetes care through effective advocacy on strong platforms and networks. 

Novo Nordisk supports and collaborates with IDF on following initiatives:


IDF’s involvement in Novo Nordisk initiatives include: 

 

Find out more about IDF


The Coalition for Access to NCD Medicines and Products 

The Coalition is a global, multi-sectorial alliance comprising +20 members from civil society, private and public sector*. 

Its aim is to increase access to essential medicines and products for noncommunicable diseases (NCDs), with a focus on reducing the impact of diabetes, hypertension, and cardiovascular disease. 

The Coalition will lead four workstreams to drive implementation of activities at the global and national levels: 

  1. Supply chain strengthening
  2. Financing and costing
  3. Health systems strengthening
  4. Advocacy

The Coalition will build on existing initiatives to address barriers that countries face in procuring, supplying, and distributing essential medicines and technologies, and ensuring they are used effectively.

The Coalition responds to WHO’s global target of >80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major NCDs in both public and private facilities. 

Background

The Coalition is an outcome of the No Empty Shelves partnership initiative between PATH and Novo Nordisk. It was launched during the UN General Assembly in New York in September 2017.

*The Coalition members include: 
PATH, Novo Nordisk, Pfizer, Inc., NCD Alliance, RTI International, Ministry of Health Kenya, Ministry of Health and Social Action Senegal, Ministry of Health Uganda, The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Access Accelerated Initiative, NCD Child, World Economic Forum, Teva Pharmaceuticals Ltd., International Pediatric Association, World Heart Federation (WHF), The George Institute for Global Health, Arnhold Institute for Global Health, International Society of Hypertension, World Hypertension League (WHL), Merck KGaA Darmstadt Germany, Sanofi, Dimagi.

 

Find out more about the Coalition